ACCREDO HEALTH SELECTED BY COTHERIX FOR VENTAVIS DISTRIBUTION

Accredo Health has announced that one of its three primary divisions, Accredo Therapeutics, has been selected by CoTherix as one of up to three specialty pharmacy providers of Ventavis (iloprost) Inhalation Solution. Ventavis, which was recently approved by the FDA for the treatment of pulmonary arterial hypertension (World Health Organization Group I), or PAH, in patients with New York Heart Association Class III or IV symptoms

Yahoo News (http://biz.yahoo.com/bw/050119/195888_2.html)